What you believe and what you value as an organization matters. Discover the DNA of our firm.
Get to know our teams and the stories of select staff members who share why they choose to work at Sands Capital.
Read about some of the latest events, partnerships, and business highlights from Sands Capital.
Sands Capital portfolio managers reflect on five powerful lessons they have learned while investing through past downturns.
As artificial intelligence (AI) becomes a part of our everyday lives, making sure it’s transparent and unbiased has become a high priority for businesses, governments, and ordinary people. In this episode of What Matters Most, Scott Frederick, a Sands Capital managing partner, explains how software startup Credo AI is helping to keep AI models responsible. Join us as we look at how Credo AI aims to lead the way in this vital new field.
At Sands Capital we encourage our investment team to think in decades not quarters. Director of Research Michael Raab, CFA discusses how culture can support the visionary research needed to find businesses creating the future.
WEG is setting new standards for sustainability and innovation by focusing on energy efficiency and renewable solutions that deliver cutting-edge technologies to align with the needs of a rapidly changing world.
Our philosophy is rooted in the belief that, over time, stock prices will reflect the earnings power and growth of the underlying businesses.
Our latest annual report offers a comprehensive view of how we add value through active stewardship.
Our newest strategy takes an unconstrained approach to seeking the best growth businesses outside of the U.S.
Sands Capital invests in innovative businesses across all stages of the growth spectrum
2016
Sands Capital (2016 - 2022)
Arlington, VA | Managing Partner
Enzymatics Inc. (2013 - 2015)
Beverly, MA | CEO
Stemgent Inc. (2008 - 2013)
Cambridge, MA | Founder, CEO
Upstate Inc. (2002 - 2004)
Charlottesville, VA | President
University of Virginia
MBA | Darden School of Business
University of Surrey
Chemical Engineering
Ian is an executive managing partner of the Sands Capital Life Sciences Pulse strategy and an executive managing director. He joined Sands Capital in 2016.
Ian is a serial entrepreneur and has 25 years of experience starting and investing in life sciences technology businesses as an angel, venture, and private equity investor. Ian has served as a founder, CEO, chief financial officer, chief operating officer, chairman, director, and advisor to a number of privately held life science product and service businesses. He has focused on cell signaling, drug screening, genomics, sequencing, cancer diagnostics, and cell culture at all stages of business development from initiation through profitability to trade sale. Before joining Sands Capital, Ian was the chairman and CEO of Enzymatics (now Qiagen); founder and CEO of Stemgent (now Reprocell), a stem and iPS cell life sciences tool company; and president of Upstate (now MilliporeSigma), a leading provider of cell signaling research products and services. Ian was also a founding investor in Firefly BioWorks and Genometry, both of which are Sands Capital Ventures investments.
Ian received a degree in chemical engineering from the University of Surrey in the U.K. and an MBA from the UVA Darden School of Business.
Something has gone wrong, check that all fields have been filled in correctly. If you have adblock, disable it.
Notice for non-US Investors